CoChat

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

Open access
Meliani, Amine, Boisgerault, Florence, Hardet, Romain, Marmier, Solenne, Collaud, Fanny, Ronzitti, Giuseppe, Leborgne, Christian, Costa Verdera, Helena, Simon Sola, Marcelo, Charles, Severine, Vignaud, Alban, van Wittenberghe, Laetitia, Manni, Giorgia, Christophe, Olivier, Fallarino, Francesca, Roy, Christopher, Michaud, Alicia, Ilyinskii, Petr, Kishimoto, Takashi Kei, Mingozzi, Federico · 2018 · Nature Communications

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

Gene therapy mediated by recombinant adeno-associated virus (AAV) vectors is a promising treatment for systemic monogenic diseases. However, vector immunogenicity represents a major limitation to gene transfer with AAV vectors, particularly for vector re-administration. Here, we demonstrate that synthetic vaccine particles encapsulating rapamycin (SVP[Rapa]), co-administered with AAV vectors, prevents the induction of anti-capsid humoral and cell-mediated responses. This allows successful vector re-administration in mice and nonhuman primates. SVP[Rapa] dosed with AAV vectors reduces B and T cell activation in an antigen-selective manner, inhibits CD8+ T cell infiltration in the liver, and efficiently blocks memory T cell responses. SVP[Rapa] immunomodulatory effects can be transferred from treated to naive mice by adoptive transfer of splenocytes, and is inhibited by depletion of CD25+ T cells, suggesting a role for regulatory T cells. Co-administration of SVP[Rapa] with AAV vector represents a powerful strategy to modulate vector immunogenicity and enable effective vector re-administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-06621-3

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 SVP[Rapa] treatment prevents anti-AAV capsid antibody responses in mice. a Protocol outline. Male C57BL/6 mice (n = 5 per group) were treated intravenously with 4 × 1012 vg kg−1 of AAV8-luc together with SVP[Rapa] (200 µg) or with SVP[empty] control. Three weeks later, animals were challenged with 4 × 1012 vg kg−1 of AAV8-hF.IX vector mixed with either SVP[Rapa] (200 µg) or SVP[empty] control. One additional control group (n = 5) of naive animals received 4 × 1012 vg kg−1 of AAV8-hF.IX vector alone at day 21 (defined as “AAV8-hF.IX only”). b Analysis of anti-AAV8 IgG antibodies measured by ELISA (**p < 0.01, ****p < 0.0001, refers to the significance between SVP[Rapa] and SVP[empty] or AAV8-hF.IX groups). c Anti-AAV8 neutralizing antibodies (NAbs) titers on day 54. d hF.IX antigen levels in plasma on day 54 determined by ELISA. e AAV8 vector genome copy number (VGCN) per diploid genome performed after killing (day 53). f Protocol outline. Three groups of C57BL/6 male mice (n = 5 per group) were prime-boosted (days 0 and 93, arrows) with 5 × 1011 vg kg−1 of AAV8-SEAP alone, or AAV8-SEAP mixed with SVP[Rapa] (50 µg), or AAV8-SEAP mixed with SVP[Empty] control. g Anti-AAV8 IgG antibodies measured by ELISA (*p < 0.05, **p < 0.01, refers to significance between SVP[Rapa] and AAV-SEAP). h Expressed SEAP activity in serum. Data are shown as mean ± s.d. Statistical analyses were performed by two-way ANOVA with Tukey post hoc test in b, g, and h, and by unpaired, two-tail t-test in c and by one-way ANOVA with Tukey post hoc test in d and e (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns not significant)
Fig. 1 SVP[Rapa] treatment prevents anti-AAV capsid antibody responses in mice. a Protocol outline. Male C57BL/6 mice (n = 5 per group) were treated intravenously with 4 × 1012 vg kg−1 of AAV8-luc together with SVP[Rapa] (200 µg) or with SVP[empty] control. Three weeks later, animals were challenged with 4 × 1012 vg kg−1 of AAV8-hF.IX vector mixed with either SVP[Rapa] (200 µg) or SVP[empty] control. One additional control group (n = 5) of naive animals received 4 × 1012 vg kg−1 of AAV8-hF.IX vector alone at day 21 (defined as “AAV8-hF.IX only”). b Analysis of anti-AAV8 IgG antibodies measured by ELISA (**p < 0.01, ****p < 0.0001, refers to the significance between SVP[Rapa] and SVP[empty] or AAV8-hF.IX groups). c Anti-AAV8 neutralizing antibodies (NAbs) titers on day 54. d hF.IX antigen levels in plasma on day 54 determined by ELISA. e AAV8 vector genome copy number (VGCN) per diploid genome performed after killing (day 53). f Protocol outline. Three groups of C57BL/6 male mice (n = 5 per group) were prime-boosted (days 0 and 93, arrows) with 5 × 1011 vg kg−1 of AAV8-SEAP alone, or AAV8-SEAP mixed with SVP[Rapa] (50 µg), or AAV8-SEAP mixed with SVP[Empty] control. g Anti-AAV8 IgG antibodies measured by ELISA (*p < 0.05, **p < 0.01, refers to significance between SVP[Rapa] and AAV-SEAP). h Expressed SEAP activity in serum. Data are shown as mean ± s.d. Statistical analyses were performed by two-way ANOVA with Tukey post hoc test in b, g, and h, and by unpaired, two-tail t-test in c and by one-way ANOVA with Tukey post hoc test in d and e (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns not significant)CC BY · PubMed Central
Fig. 2 SVP[Rapa] treatment enables AAV8 re-administration in nonhuman primates. a Protocol outline. Male naive cynomolgus monkeys were treated i.v. with 2 × 1012 vg kg−1 of AAV8-Gaa vector and either SVP[Rapa] (3 mg kg−1, n = 2, SVP[Rapa]#1 and SVP[Rapa]#2) or SVP[empty] control (n = 1) and then challenged i.v. on day 30 with 2 × 1012 vg kg−1 of AAV8-hF.IX vector and either SVP[Rapa] or SVP[empty] control, as described above. b, c Analysis of b anti-AAV8 IgG antibodies and c anti-AAV8 IgM antibody responses measured by ELISA. d Analysis of anti-AAV8 neutralizing antibodies (NAb) measured with a cell-based neutralization assay. e Analysis of anti-AAV8 IgG secreting B cells in splenocytes measured by B ELISpot. Data are shown as individual replicates and the bars represent mean ± s.d. The dotted line indicates the threshold for positivity corresponding to 50 spot forming units (SFU) per million cells. f Plasma hF.IX antigen levels quantified by ELISA at the indicated time points following administration of AAV8-hF.IX vector. g AAV8-hF.IX vector genome copy number (VGCN) per diploid genome in liver. The symbols represent individual liver lobes (left, right, caudate and quadrate) and the bars represent the mean ± s.d. (4 liver lobes per monkey; one-way ANOVA with Tukey post hoc test, **p < 0.01, ****p < 0.0001) The arrows represent the timing of each AAV8 vector infusion
Fig. 2 SVP[Rapa] treatment enables AAV8 re-administration in nonhuman primates. a Protocol outline. Male naive cynomolgus monkeys were treated i.v. with 2 × 1012 vg kg−1 of AAV8-Gaa vector and either SVP[Rapa] (3 mg kg−1, n = 2, SVP[Rapa]#1 and SVP[Rapa]#2) or SVP[empty] control (n = 1) and then challenged i.v. on day 30 with 2 × 1012 vg kg−1 of AAV8-hF.IX vector and either SVP[Rapa] or SVP[empty] control, as described above. b, c Analysis of b anti-AAV8 IgG antibodies and c anti-AAV8 IgM antibody responses measured by ELISA. d Analysis of anti-AAV8 neutralizing antibodies (NAb) measured with a cell-based neutralization assay. e Analysis of anti-AAV8 IgG secreting B cells in splenocytes measured by B ELISpot. Data are shown as individual replicates and the bars represent mean ± s.d. The dotted line indicates the threshold for positivity corresponding to 50 spot forming units (SFU) per million cells. f Plasma hF.IX antigen levels quantified by ELISA at the indicated time points following administration of AAV8-hF.IX vector. g AAV8-hF.IX vector genome copy number (VGCN) per diploid genome in liver. The symbols represent individual liver lobes (left, right, caudate and quadrate) and the bars represent the mean ± s.d. (4 liver lobes per monkey; one-way ANOVA with Tukey post hoc test, **p < 0.01, ****p < 0.0001) The arrows represent the timing of each AAV8 vector infusionCC BY · PubMed Central
Fig. 3 Enhanced liver transduction via repeated AAV8 vector administrations in nonhuman primates. a Dual immunofluorescence staining of Gaa and hF.IX in livers from nonhuman primates treated with AAV8 vectors together with SVP[Rapa] (n = 2, SVP[Rapa]#1 and SVP[Rapa]#2, 3 mg kg−1) or SVP[empty] control (n = 1). 95 days post AAV8-Gaa administration, liver lobes were collected and stained for Gaa (shown in green), hF.IX (shown in red) and Gaa/hF.IX co-localization (merge, shown in yellow) and nuclei are DAPI-stained (Blue). Scale bar 20 μm. b Quantification of cells positive for Gaa, hF.IX and double-positives to Gaa/hF.IX in liver lobes. Data are shown as mean ± s.d. (four different images per lobe were analyzed for each animal)
Fig. 3 Enhanced liver transduction via repeated AAV8 vector administrations in nonhuman primates. a Dual immunofluorescence staining of Gaa and hF.IX in livers from nonhuman primates treated with AAV8 vectors together with SVP[Rapa] (n = 2, SVP[Rapa]#1 and SVP[Rapa]#2, 3 mg kg−1) or SVP[empty] control (n = 1). 95 days post AAV8-Gaa administration, liver lobes were collected and stained for Gaa (shown in green), hF.IX (shown in red) and Gaa/hF.IX co-localization (merge, shown in yellow) and nuclei are DAPI-stained (Blue). Scale bar 20 μm. b Quantification of cells positive for Gaa, hF.IX and double-positives to Gaa/hF.IX in liver lobes. Data are shown as mean ± s.d. (four different images per lobe were analyzed for each animal)CC BY · PubMed Central
Fig. 4 Inhibition of anti-AAV8 capsid cellular and humoral responses with SVP[Rapa] co-administration. a CD8 T cell infiltrates in the liver. Livers from animals treated in Fig. 1a were collected after killing on day 53 and evaluated for CD8 mRNA expression by quantitative PCR using the ΔΔCt method relative to housekeeping gene and to average of untreated mice. b–d Male C57BL/6 mice were treated with 4 × 1012 vg kg−1 of AAV8-VP1 vector together with SVP[Rapa] or with SVP[empty] control. 14 days later, spleens were collected for B and T cell assays. b Analysis of T cell recall responses after overnight stimulation with an AAV8 peptide pool in splenocytes measured by IFN-γ ELISpot and c anti-AAV8 IgG and IgM secreting B cell responses in splenocytes measured by B ELISpot. d Frequency of B220+ CD19+ B cells in spleens measured by flow cytometry. e–i Male C57BL/6 mice were treated with 4 × 1012 vg kg−1 of AAV8-luc vector together with SVP[Rapa] or with SVP[empty] control. 14 days later, animals were sacrificed. e Gating of germinal center (GC) B cells (CD95+ GL7+) are shown in representative flow cytometry plot. Cells were gated on B220+IgD− cells. Shown is a mouse from the SVP[empty] control group. f Frequency of GC B cells (CD95+ GL7+) in lymph nodes of treated mice determined by flow cytometry as shown in e; g frequency of CD25+ FoxP3+ regulatory T cells in lymph nodes; h frequency of CXCR5+ PD1+ Foxp3+ follicular regulatory T (Tfr) cells and i frequency of CXCR5+PD1+FoxP3− follicular helper T (Tfh) cells in lymph nodes. SVP[Rapa] treatment consisted of 200 µg of rapamycin. Data are shown as mean ± s.d. Statistical analyses were performed by one-way ANOVA with Tukey post hoc test in a and by unpaired, two-tail t-test in b–d, f–i (n = 5 in a–d, n = 20 in f–i. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)
Fig. 4 Inhibition of anti-AAV8 capsid cellular and humoral responses with SVP[Rapa] co-administration. a CD8 T cell infiltrates in the liver. Livers from animals treated in Fig. 1a were collected after killing on day 53 and evaluated for CD8 mRNA expression by quantitative PCR using the ΔΔCt method relative to housekeeping gene and to average of untreated mice. b–d Male C57BL/6 mice were treated with 4 × 1012 vg kg−1 of AAV8-VP1 vector together with SVP[Rapa] or with SVP[empty] control. 14 days later, spleens were collected for B and T cell assays. b Analysis of T cell recall responses after overnight stimulation with an AAV8 peptide pool in splenocytes measured by IFN-γ ELISpot and c anti-AAV8 IgG and IgM secreting B cell responses in splenocytes measured by B ELISpot. d Frequency of B220+ CD19+ B cells in spleens measured by flow cytometry. e–i Male C57BL/6 mice were treated with 4 × 1012 vg kg−1 of AAV8-luc vector together with SVP[Rapa] or with SVP[empty] control. 14 days later, animals were sacrificed. e Gating of germinal center (GC) B cells (CD95+ GL7+) are shown in representative flow cytometry plot. Cells were gated on B220+IgD− cells. Shown is a mouse from the SVP[empty] control group. f Frequency of GC B cells (CD95+ GL7+) in lymph nodes of treated mice determined by flow cytometry as shown in e; g frequency of CD25+ FoxP3+ regulatory T cells in lymph nodes; h frequency of CXCR5+ PD1+ Foxp3+ follicular regulatory T (Tfr) cells and i frequency of CXCR5+PD1+FoxP3− follicular helper T (Tfh) cells in lymph nodes. SVP[Rapa] treatment consisted of 200 µg of rapamycin. Data are shown as mean ± s.d. Statistical analyses were performed by one-way ANOVA with Tukey post hoc test in a and by unpaired, two-tail t-test in b–d, f–i (n = 5 in a–d, n = 20 in f–i. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)CC BY · PubMed Central
Fig. 5 Control of anti-AAV8 capsid memory T cell responses with SVP[Rapa]. a Protocol outline. Male C57BL/6 mice (n = 4) were treated i.v. with AAV8-luc vector (2.5 × 1012 vg kg−1) together with SVP[Rapa] or with SVP[empty] on day 0 and with a second dose on day 77 with AAV8-luc vector (5 × 1011 vg kg−1) together with SVP[Rapa] or SVP[empty] control. Spleens were collected at day 19 and day 80 after priming and boosting, respectively. b IFN-γ ELISpot responses after 7 days of in vitro restimulation with an AAV8 peptide pool performed in splenocytes collected 19 or 80 days following initial vector injection. The symbols represent individual animals and the bars represent mean ± s.d. (n = 4, ***p < 0.05, ns not significant, two-tailed, unpaired t-test). c Protocol outline. Donor mice (n = 15) were left untreated or treated i.v with 4 × 1011 vg kg−1 of AAV8-RFP vector. 62 days later, spleens were collected and CD4+ T cells were purified. 1 × 107 of CD4+ T cells were then adoptively transferred into four groups of recipient mice (n = 6). Animals were treated with 4 × 1011 vg kg−1 of AAV8-RFP vector together with SVP[Rapa] or SVP[empty] control on day 1 post adoptive transfer and with 4 × 1011 vg kg−1 of AAV8-SEAP together with SVP[Rapa] or SVP[empty] on 21 post adoptive transfer. The tabular legend represents the summary of the treatment groups and the symbols represent the different cohorts of recipient mice. d, e Analysis of anti-AAV8 IgG antibodies in donor mice (d) and in recipient mice post adoptive transfer (e) measured by ELISA. d, e Data shown as mean ± s.d. (n = 6, *p < 0.05, ****p < 0.0001, refers to significance between cohorts 3 and 4 as determined by two-way ANOVA with Tukey post hoc test). SVP[Rapa] treatment consisted of 50 µg of rapamycin
Fig. 5 Control of anti-AAV8 capsid memory T cell responses with SVP[Rapa]. a Protocol outline. Male C57BL/6 mice (n = 4) were treated i.v. with AAV8-luc vector (2.5 × 1012 vg kg−1) together with SVP[Rapa] or with SVP[empty] on day 0 and with a second dose on day 77 with AAV8-luc vector (5 × 1011 vg kg−1) together with SVP[Rapa] or SVP[empty] control. Spleens were collected at day 19 and day 80 after priming and boosting, respectively. b IFN-γ ELISpot responses after 7 days of in vitro restimulation with an AAV8 peptide pool performed in splenocytes collected 19 or 80 days following initial vector injection. The symbols represent individual animals and the bars represent mean ± s.d. (n = 4, ***p < 0.05, ns not significant, two-tailed, unpaired t-test). c Protocol outline. Donor mice (n = 15) were left untreated or treated i.v with 4 × 1011 vg kg−1 of AAV8-RFP vector. 62 days later, spleens were collected and CD4+ T cells were purified. 1 × 107 of CD4+ T cells were then adoptively transferred into four groups of recipient mice (n = 6). Animals were treated with 4 × 1011 vg kg−1 of AAV8-RFP vector together with SVP[Rapa] or SVP[empty] control on day 1 post adoptive transfer and with 4 × 1011 vg kg−1 of AAV8-SEAP together with SVP[Rapa] or SVP[empty] on 21 post adoptive transfer. The tabular legend represents the summary of the treatment groups and the symbols represent the different cohorts of recipient mice. d, e Analysis of anti-AAV8 IgG antibodies in donor mice (d) and in recipient mice post adoptive transfer (e) measured by ELISA. d, e Data shown as mean ± s.d. (n = 6, *p < 0.05, ****p < 0.0001, refers to significance between cohorts 3 and 4 as determined by two-way ANOVA with Tukey post hoc test). SVP[Rapa] treatment consisted of 50 µg of rapamycinCC BY · PubMed Central
Fig. 6 Antigen-specificity of SVP[Rapa] treatment and role of regulatory T cells. a Protocol outline. Male C57BL/6 mice (n = 5) were first injected i.v. with 4 × 1012 vg kg−1 of AAV8-luciferase vector together with SVP[Rapa] or with SVP[empty] control. Animals were then challenged i.v. on day 21 with 4 × 1012 vg kg−1 of AAV8-hF.IX vector or AAV5-hF.IX vector or injected s.c. with hF.IX in complete Freund’s adjuvant (cFA). b Anti-AAV8 IgG in animals primed with AAV8-luc and challenged with AAV8-hF.IX. c Anti-AAV5 IgG in animals primed with AAV8-luc and challenged with AAV5-hF.IX, and d anti-hF.IX IgG antibodies determined by ELISA in animals primed with AAV8-luc and challenged with hF.IX protein in cFA. e Protocol outline. Donor mice (n = 5) were left untreated or treated i.v. with 4 × 1011 vg kg−1 of AAV8-luciferase vector together with SVP[Rapa] or SVP[empty] control. 14 days later, spleens were harvested and 3 × 107 splenocytes were adoptively transferred into recipient mice (n = 5). All animals were then treated one day later with 4 × 1011 vg kg−1 of AAV8-hF.IX vector. f Anti-AAV8 IgG antibodies measured 14 days post AAV8-hF.IX vector injection and measured by ELISA. g Protocol outline. Male C57BL/6 mice (n = 5 per group) were treated i.v. with 4 × 1012 vg kg−1 of AAV8-luciferase vector together with SVP[Rapa] or SVP[empty] control on day 0, followed by Tregs depletion (anti-CD25, clone PC61, 200 µg per mouse) on days 19 and 20. All animals were then challenged with 4 × 1012 vg kg−1 of AAV8-hF.IX vector alone on day 21. h Analysis anti-AAV8 IgG antibodies measured by ELISA. SVP[Rapa] treatment consisted of 200 µg of rapamycin. Data are shown as mean ± s.d. Statistical analyses were performed by two-way ANOVA with Tukey post hoc test in b–d, by one-way ANOVA with Tukey post hoc test in f, and by non-parametric unpaired, two-tail t-test in h (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)
Fig. 6 Antigen-specificity of SVP[Rapa] treatment and role of regulatory T cells. a Protocol outline. Male C57BL/6 mice (n = 5) were first injected i.v. with 4 × 1012 vg kg−1 of AAV8-luciferase vector together with SVP[Rapa] or with SVP[empty] control. Animals were then challenged i.v. on day 21 with 4 × 1012 vg kg−1 of AAV8-hF.IX vector or AAV5-hF.IX vector or injected s.c. with hF.IX in complete Freund’s adjuvant (cFA). b Anti-AAV8 IgG in animals primed with AAV8-luc and challenged with AAV8-hF.IX. c Anti-AAV5 IgG in animals primed with AAV8-luc and challenged with AAV5-hF.IX, and d anti-hF.IX IgG antibodies determined by ELISA in animals primed with AAV8-luc and challenged with hF.IX protein in cFA. e Protocol outline. Donor mice (n = 5) were left untreated or treated i.v. with 4 × 1011 vg kg−1 of AAV8-luciferase vector together with SVP[Rapa] or SVP[empty] control. 14 days later, spleens were harvested and 3 × 107 splenocytes were adoptively transferred into recipient mice (n = 5). All animals were then treated one day later with 4 × 1011 vg kg−1 of AAV8-hF.IX vector. f Anti-AAV8 IgG antibodies measured 14 days post AAV8-hF.IX vector injection and measured by ELISA. g Protocol outline. Male C57BL/6 mice (n = 5 per group) were treated i.v. with 4 × 1012 vg kg−1 of AAV8-luciferase vector together with SVP[Rapa] or SVP[empty] control on day 0, followed by Tregs depletion (anti-CD25, clone PC61, 200 µg per mouse) on days 19 and 20. All animals were then challenged with 4 × 1012 vg kg−1 of AAV8-hF.IX vector alone on day 21. h Analysis anti-AAV8 IgG antibodies measured by ELISA. SVP[Rapa] treatment consisted of 200 µg of rapamycin. Data are shown as mean ± s.d. Statistical analyses were performed by two-way ANOVA with Tukey post hoc test in b–d, by one-way ANOVA with Tukey post hoc test in f, and by non-parametric unpaired, two-tail t-test in h (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 281

Metadata

Authors
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., Vignaud, A., van Wittenberghe, L., Manni, G., Christophe, O., Fallarino, F., Roy, C., Michaud, A., Ilyinskii, P., Kishimoto, T. K., & Mingozzi, F.
Affiliations
  • Inserm (FR)
  • University of Perugia (IT)
  • Université Paris-Sud (FR)
  • Selecta Biosciences (United States) (US)
Corresponding author
Mingozzi, Federico
Venue
Nature Communications
Published
2018-10-05
Volume
9
Issue
1
Pages
4098-4098
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2894600652
Cited by
265
References
60
Citations by year
2026: 27 · 2025: 24 · 2024: 30 · 2023: 33 · 2022: 44 · 2021: 32 · 2020: 40 · 2019: 30 · 2018: 4
FWCI
16.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • E-Rare
  • European Commission (667751, FP7-PEOPLE-2012-CIG, 333628, 617432)
  • FP7 People: Marie-Curie Actions (FP7-PEOPLE-2012-CIG)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
adeno-associated virus vectors, rapamycin, regulatory T cells, memory T cells, adoptive transfer, CD25+ T cells, gene therapy
MeSH terms
Dependovirus, Animals, Drug Evaluation, Preclinical, Genetic Vectors, Immunity, Cellular, Immunosuppressive Agents, Macaca fascicularis, Male, Mice, Inbred C57BL, T-Lymphocytes, Genetic Therapy, Sirolimus, Nanoparticles, Immunity, Humoral

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. https://app.cochat.ai/papers/10.1038/s41467-018-06621-3
The paper
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., Vignaud, A., van Wittenberghe, L., Manni, G., Christophe, O., Fallarino, F., Roy, C., Michaud, A., Ilyinskii, P., Kishimoto, T. K., & Mingozzi, F. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nature Communications. https://doi.org/10.1038/s41467-018-06621-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.